Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 3/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.65 |
| ▸ | DYRK2 | Q92630 | 3/20 | 0.65 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.65 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.62 |
| ▸ | TNIK | Q9UKE5 | 11/20 | 0.59 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3767861 | 0.91 | TNIK (0.61) | CLK1DYRK1ADYRK2DYRK1BMAP4K1 | |
| SCHEMBL7909336 | 0.86 | CLK1 (0.65) | CLK1DYRK1ADYRK2DYRK1BMAP4K1 | |
| SCHEMBL3771781 | 0.84 | MAP4K1 (0.62) | CLK1DYRK1ADYRK2DYRK1BMAP4K1 | |
| SCHEMBL8941800 | 0.80 | CLK1 (0.81) | CLK1DYRK1ADYRK2DYRK1BTNIK | |
| SCHEMBL3765725 | 0.79 | MAP4K1 (0.63) | CLK1DYRK1AMAP4K1TNIKNTRK1 | |
| SCHEMBL3769693 | 0.78 | KIT (0.69) | DYRK1AMAP4K1PIK3CA | |
| SCHEMBL28587387 | 0.78 | MAP4K1 (0.79) | DYRK1AMAP4K1NTRK1 | |
| SCHEMBL28591930 | 0.77 | MAP4K1 (1.00) | MAP4K1TNIK | |
| SCHEMBL722074 | 0.77 | MAP3K11 (0.71) | CLK1DYRK1ADYRK2DYRK1BTNIK | |
| SCHEMBL21592505 | 0.77 | TNIK (0.75) | CLK1DYRK1ADYRK2DYRK1BMAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | GlaxoSmithKline, LLC | 2012-09-20 | — | — | US | claimed |
| WO-2010049173-A1 | USE OF INHIBITORS OF HOST KINASES FOR THE TREATMENT OF INFECTIOUS DISEASES | CENIX BIOSCIENCE GMBH (DE) | 2010-05-06 | — | — | WO | claimed |
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | GLAXOSMITHKLINE LLC | 2009-09-17 | — | — | US | claimed |
| EP-1828180-A1 | 1H-PYRROLO[2,3-BETA]PYRIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-05 | — | — | EP | claimed |
| WO-2006063167-A1 | 1H-PYRROLO[2,3-B]PYRIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-06-15 | — | — | WO | claimed |
| WO-2021006707-A1 | USE OF SGK1 INHIBITOR AS THERAPEUTIC AGENT FOR INFLAMMATORY NEUROLOGICAL DISEASES | 한양대학교 산학협력단 | 2021-01-14 | — | — | WO | disclosed |
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | GlaxoSmithKline, LLC | 2012-09-20 | — | — | US | disclosed |
| WO-2010049173-A1 | USE OF INHIBITORS OF HOST KINASES FOR THE TREATMENT OF INFECTIOUS DISEASES | CENIX BIOSCIENCE GMBH (DE) | 2010-05-06 | — | — | WO | disclosed |
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | GLAXOSMITHKLINE LLC | 2009-09-17 | — | — | US | disclosed |
| EP-1828180-A1 | 1H-PYRROLO[2,3-BETA]PYRIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006063167-A1 | 1H-PYRROLO[2,3-B]PYRIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | SGK1, SGK2, SGK3 | CLK1 254/4885DYRK1A 378/4885DYRK2 348/4885 |
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | SGK1, SGK2, SGK3 | CLK1 262/4885DYRK1A 360/4885DYRK2 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.